Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2023
  • Case
  • HBS Case Collection

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker
  • Format:Print
  • | Language:English
  • | Pages:24
ShareBar

Abstract

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful therapy was on track but faced an unclear future. Overseeing the human trials of a refined second-generation drug candidate, Amy had led the company back from the “valley of death” after Cleave’s initial offering resulted in off-target toxicity. Still, after completing multiple dose escalation cohorts, Cleave’s scientists told Amy that they could not draw any definitive conclusions about the benefits of the drug. Amy and her team knew the importance of speed and capital in the high-risk business of oncology drug development where success often takes more resources and time than expected and competitors lurk. Nearing the close of a five-year investment window, should the thinly staffed Cleave 2.0 continue to recruit patients and clear dosing cohorts at a rapid rate, or should Amy prioritize funding and partnership discussions?

This case is suitable as a general business case for undergraduate and MBA students of any level on strategy, entrepreneurship, health care innovation, biopharma, cancer, FDA’s role in biopharma, funding early-stage biopharma ventures, biopharma clinical trials, and the healthcare industry.

Keywords

Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

Citation

Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
  • Educators
  • Purchase

About The Author

Regina E. Herzlinger

General Management
→More Publications

More from the Authors

    • August 2023
    • Faculty Research

    Parexel (B): The Future of the CRO Industry

    By: Regina E. Herzlinger and Ben Creo
    • 3 Jun 2023
    • Faculty Research

    Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen

    By: Regina E. Herzlinger
    • April 2023
    • Faculty Research

    Note on Healthcare in Ghana

    By: Regina E. Herzlinger and Ben Creo
More from the Authors
  • Parexel (B): The Future of the CRO Industry By: Regina E. Herzlinger and Ben Creo
  • Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen By: Regina E. Herzlinger
  • Note on Healthcare in Ghana By: Regina E. Herzlinger and Ben Creo
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College